SCHEMBL5487653

SCHEMBL5487653

Cc1ccc(C(=O)NN)cc1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 1/20 0.56
KMT2A Q03164 3/20 0.54
TAS1R3 Q7RTX0 2/20 0.54
TAS1R1 Q7RTX1 2/20 0.54
MEN1 O00255 1/20 0.53
MPO P05164 1/20 0.52
CYP3A4 P08684 1/20 0.52
KDM5A P29375 1/20 0.52
BLM P54132 1/20 0.52
GFER P55789 1/20 0.52
PMP22 Q01453 1/20 0.52
HIF1A Q16665 1/20 0.52
MAPT P10636 2/20 0.52
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
MAPK14 Q16539 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
KDM4E B2RXH2 2/20 0.50
ALDH1A1 P00352 2/20 0.50
HDAC3 O15379 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2810590 0.86 MAPT (0.50) NR1H4MPOCYP3A4KDM5ABLM
SCHEMBL22441042 0.86 MYC (0.55) MPOCYP3A4KDM5ABLMGFER
SCHEMBL5301581 0.85 MAPK14 (0.54) NR1H4KMT2AMEN1MPOCYP3A4
SCHEMBL1628213 0.84 ALDH1A1 (0.57) MPOCYP3A4KDM5ABLMGFER
SCHEMBL4809042 0.84 MAPT (0.66) MPOCYP3A4KDM5ABLMGFER
SCHEMBL9646049 0.82 MYC (0.53) KMT2AMEN1MPOCYP3A4KDM5A
SCHEMBL15006963 0.82 HDAC1 (0.51) MPOCYP3A4KDM5ABLMGFER
SCHEMBL1459893 0.82 OGG1 (0.55) MPOCYP3A4KDM5ABLMGFER
SCHEMBL18423953 0.82 HDAC1 (0.71) KMT2AMPOCYP3A4KDM5ABLM
SCHEMBL29225419 0.82 ALDH1A1 (0.55) KMT2AMEN1MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119977832-A Benzoyl hydrazine antineoplastic compound and preparation method and application thereof 江苏海洋大学 2025-05-13 CN claimed
CN-119977832-A Benzoyl hydrazine antineoplastic compound and preparation method and application thereof 江苏海洋大学 2025-05-13 CN disclosed
WO-2023073115-A1 PROTEIN AGGREGATION INHIBITING COMPOUNDS FOR PLANT DISEASE CONTROL MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2023-05-04 WO disclosed
US-11634391-B2 Compounds which are inhibitors of Notum UCL BUSINESS LTD (GB) 2023-04-25 US disclosed
CN-114230517-A Method for processing eltrombopag 杭州煌森生物科技有限公司 2022-03-25 CN disclosed
EP-3843844-A1 COMPOUNDS UCL Business Ltd (GB) 2021-07-07 EP disclosed
CN-113024465-A Preparation method of stable-performance eltrombopag 杭州煌森生物科技有限公司 2021-06-25 CN disclosed
US-20210171475-A1 COMPOUNDS UCL BUSINESS LTD (GB) 2021-06-10 US disclosed
WO-2020043866-A1 COMPOUNDS UCL BUSINESS LTD (GB) 2020-03-05 WO disclosed
US-20170253569-A1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF REGENTS OF THE UNIVERSITY OF MINNESOTA 2017-09-07 US disclosed
EP-1819341-A2 IL-12 MODULATORY COMPOUNDS Synta Pharmaceuticals Corporation (US) 2007-08-22 EP disclosed
US-7166623-B2 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-01-23 US disclosed
US-7166623-B2 2′-Methyl-5′-(1,3,4-oxadiazol-2-yl)-1,1′-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-01-23 US disclosed
WO-2006053227-A2 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2006-05-18 WO disclosed
EP-0088729-B1 USE OF METAL COMPLEXES OF HYDRAZONES AS PIGMENTS CIBA-GEIGY AG (CH) 1987-07-29 EP disclosed
US-4612014-A Use of metal complexes of hydrazones as pigments CIBA-GEIGY CORPORATION (US) 1986-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11634391-B2 Compounds which are inhibitors of Notum NOTUM, GOT2, GOT1 NR1H4 257/4885KMT2A 4180/4885TAS1R3 4367/4885
US-20210171475-A1 COMPOUNDS GOT2, GOT1, OAT NR1H4 68/4885KMT2A 3672/4885TAS1R3 4049/4885
US-20170253569-A1 THIAZOLIDINONE COMPOUNDS AND USE THEREOF OPRL1, OPRD1, OPRK1 NR1H4 7/4885KMT2A 3536/4885TAS1R3 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.